Cadence Pharmaceuticals Inc

Cadence Pharmaceuticals — Investor Presentation (January 2009)

30 slides from Cadence Pharmaceuticals's investor presentation, Jan 12, 2009

  1. Slide 1: Corporate Overview

    Slide 1: Corporate Overview

    Corporate Overview Exhibit 99.1 Improving the lives of hospitalized patients January 2009

  2. Slide 2: Theodore R. Schroeder, President, CEO & Co-Founder

    Slide 2: Theodore R. Schroeder, President, CEO & Co-Founder

    Theodore R. Schroeder President, CEO & Co-Founder

  3. Slide 3: Forward-looking statements

    Slide 3: Forward-looking statements

    Forward-looking statements This presentation includes forward-looking statements. Words such as “believes,” “plans,” “expects,” “anticipates,” and “will” are intended to identify forward-looking statements, and are based on our current beliefs and expectations. They include statements regarding: our

  4. Slide 4: Cadence: highlights

    Slide 4: Cadence: highlights

    Cadence: highlights Hospital-focused business strategy Acquire, develop and commercialize late-stage products Target $50+ billion US hospital market with focused sales force Acetavance – Phase III for acute pain and fever (US) EU market leader; significant US market opportunity Opioid-sparing potent

  5. Slide 5: Intravenous acetaminophen pipeline

    Slide 5: Intravenous acetaminophen pipeline

    Acetavance TM Acute pain - adults Acute pain - pediatrics Fever - adults Fever - pediatrics Preclinical Phase I Phase II Phase III Acute pain - adults Acute pain - pediatrics Fever - adults Fever - pediatrics Preclinical Phase I Phase II Phase III intravenous acetaminophen

  6. Slide 6: Product overview

    Slide 6: Product overview

    Acetavance TM : product overview Oral acetaminophen - most widely used drug for pain and fever Available in US for 50+ years Active ingredient in Tylenol ® and >300 other medications Acetavance – proprietary IV formulation Marketed by BMS in Europe since 2002 (Perfalgan ) Cadence acquired US and Can

  7. Slide 7: Limitations of current IV therapies

    Slide 7: Limitations of current IV therapies

    Acetavance TM : limitations of current IV therapies Opioids NSAIDs Sedation Nausea Vomiting Constipation Headache Cognitive impairment Respiratory depression Black Box Warning Bleeding GI complications Kidney complications Cardiovascular risks Prolonged recovery Increased length of stay Higher costs

  8. Slide 8: Foundation of multi-modal analgesia

    Slide 8: Foundation of multi-modal analgesia

    Acetavance TM : foundation of multi - modal analgesia IV acetaminophen + opioids IV acetaminophen +/- opioids IV acetaminophen Sinatra, et al. Anesthesiology. April 2005 Baseline analgesic post-op Add opioids if pain increases Result : >33% decrease in opioids Superior pain relief Better patient sat

  9. Slide 9: IV acetaminophen leads EU market

    Slide 9: IV acetaminophen leads EU market

    Acetavance TM : IV acetaminophen leads EU market European IV Acetaminophen Sales Source: IMS data, company estimates

  10. Slide 10: IV acetaminophen leads EU market

    Slide 10: IV acetaminophen leads EU market

    Acetavance TM : IV acetaminophen leads EU market 20% Mar 04 Launch Date 2007 Unit Share* Jun 02 47% Nov 02 17% Jun 03 22% Apr 04 27% Dec 04 8% Total EU market 21% EU IV Acetaminophen Sales Performance * Unit share of all injectable analgesics Source: IMS data

  11. Slide 11: Large US market opportunity

    Slide 11: Large US market opportunity

    Acetavance TM : large US market opportunity US and EU injectable analgesics markets are similarly sized ~80 million IV acetaminophen units sold in Europe in 2007 $8-10 US price expected for Acetavance Sources: IMS data, company estimates

  12. Slide 12: Significant physician support

    Slide 12: Significant physician support

    Acetavance TM : significant physician support Market survey of 126 US physicians suggests readiness to adopt Source: IMS market research 2007

  13. Slide 13: Clear path to NDA

    Slide 13: Clear path to NDA

    Acetavance TM : clear path to NDA Safety 505(b)(2) NDA Reformulation of one of the most widely used drugs in the US Ability to reference studies conducted by others, including extensive literature Safety Safety consistent with placebo, including hepatic safety >2,000 subjects studied in clinical tri

  14. Slide 14: capence

    Slide 14: capence

    capence c&

  15. Slide 15: No accumulation over hours

    Slide 15: No accumulation over hours

    Acetavance TM : no accumulation over 48 hours Study 101: PK study comparing IV to oral acetaminophen (n=38) Mean acetaminophen concentration over time profiles for each treatment six hour IV or PO dosing regimen Arrow (dosing time), error bar (standard error), solid dot and line (arithmetic mean ace

  16. Slide 16: Hepatic safety similar to placebo

    Slide 16: Hepatic safety similar to placebo

    Acetavance TM : hepatic safety similar to placebo Acetavance Placebo Single dose studies 3.1% (12/381) 8.2% (12/146) Multiple dose studies 3.0% (8/268) 5.2% (14/269) TOTAL 3.1% (20/649) 6.3% (26/415) * AE reports are regardless of relatedness and majority were assessed by investigator to be unrelate

  17. Slide 17: Pivotal study in post-op pain

    Slide 17: Pivotal study in post-op pain

    IV acetaminophen placebo p-value Acetavance TM : pivotal study in post - op pain Sinatra, et al. Anesthesiology, V 102, No. 4, April 2005. Sum of pain intensity difference over 24h 0.4 -235 <0.0001 Weighted sums of pain relief over 6h 6.6 2.2 <0.05 Good/excellent evaluation at 24h 41% 23% <0.01 Morp

  18. Slide 18: Pivotal study in fever

    Slide 18: Pivotal study in fever

    Acetavance TM : IV acetaminophen placebo p-value pivotal study in fever Primary endpoint: WSTD6 Mean (SD) -3.7 (3.58) -0.7 (3.32) 0.001 Median -3.7 -1.2 Range -9.8 to 5.5 -10.0 to 8.2 Secondary endpoints WSTD3 -0.9 0.7 <0.0001 Max temp reduction T0 to T6h 1.3 0.9 <0.05 % subjects w/ temp <38°C T0 to

  19. Slide 19: Be RORETETTTY

    Slide 19: Be RORETETTTY

    Be RORETETTTY

  20. Slide 20: Strong intellectual property

    Slide 20: Strong intellectual property

    Acetavance TM : strong intellectual property Issued US process & product-by-process patent Issued US formulation patent R * Acetaminophen in solution Acetaminophen polymers Free radical formation + Formulation must protect acetaminophen from O degradation Covers process for removing oxygen from a so

  21. Slide 21: Omigard

    Slide 21: Omigard

    Omigard TM omiganan 1% aqueous gel Preclinical Phase I Phase II Phase III Catheter-related infections Other infections Preclinical Phase I Phase II Phase III Catheter-related infections Other infections

  22. Slide 22: Omigard: product overview

    Slide 22: Omigard: product overview

    Omigard TM : product overview Topical antimicrobial for catheter-related infections Bactericidal and fungicidal Rapid and prolonged effect No acquired resistance observed Excellent safety profile Convenient application Cadence acquired North American and European rights

  23. Slide 23: Omigard: significant unmet need

    Slide 23: Omigard: significant unmet need

    Omigard TM : significant unmet need Catheters are leading cause of BSI 325,000 catheter-related BSIs annually 40,000 - 80,000 deaths Mounting pressure to lower infection rates Mandatory hospital reporting Changes in CMS reimbursement $25,000 per infection Significant limitations with current standar

  24. Slide 24: Omigard: large market opportunity

    Slide 24: Omigard: large market opportunity

    Omigard TM : large market opportunity 20 million central lines placed in US annually 11 million CVCs 7 million arterial lines 2 million PICCs 9% CAGR 3 to 4 applications of Omigard per catheter Dressing change and reapplication every 3 days >50 million potential applications of Omigard in US annuall

  25. Slide 25: Omigard: clinical development plan

    Slide 25: Omigard: clinical development plan

    Omigard TM : clinical development plan Special Protocol Assessment (SPA) with FDA Single confirmatory Phase III trial required for approval Primary endpoint: Local Catheter Site Infection (LCSI) 42% LCSI reduction ( p=0.03 ) demonstrated in previous Phase III study (n=1,407) Phase III CLIRS trial: C

  26. Slide 26: Omigard: perceived as major advancement

    Slide 26: Omigard: perceived as major advancement

    Omigard TM : perceived as major advancement Harris Interactive, Inc. November 2006 85% Combined Extremely Favorable/Very Favorable Impression Physicians (n=230) Nurses (n=75) Pharmacists (n=41) 0% 2% 13% 42% 43% 0% 1% 16% 40% 43% 0% 0% 12% 46% 41% Not at all Favorable Extremely Favorable

  27. Slide 27: Cadence: key milestones

    Slide 27: Cadence: key milestones

    Cadence: Omigard Phase III CLIRS results 1Q09 Acetavance NDA submission 2Q09 Omigard NDA submission 2Q09 key milestones

  28. Slide 28: Cadence: financial position

    Slide 28: Cadence: financial position

    Cadence: financial position 12 Months Ended 12/31/07 (MM) 9 Months Ended 9/30/08 (MM) Operating expenses $54.2 $42.9 Cash and cash equivalents (1) $55.4 $61.1 Shares outstanding (1) 29.1 38.4 (1) Results for Months Ended 9/30/08 include net proceeds of approx. $49.1 million from a registered direct

  29. Slide 29: Cadence: highlights

    Slide 29: Cadence: highlights

    Cadence: highlights Clear path to 505(b)(2) NDA Pivotal efficacy trials complete New data support safety profile Reformulation of most widely used pain drug in US Significant US market opportunity #1 injectable pain drug in Europe Pricing upside in US vs. Europe SPA path to NDA Enrollment complete i

  30. Slide 30: Improving the lives of hospitalized patients

    Slide 30: Improving the lives of hospitalized patients

    NASDAQ: CADX Improving the lives of hospitalized patients

Source: SEC EDGAR · 8-K filed Jan 12, 2009

More decks from Cadence Pharmaceuticals Inc